Medexus Pharmaceuticals Inc (MDP) AI Stock Analysis

• Market Cap: C$94.19M
• Dividend Yield: N/A
• Average Volume (3M): 46.91K
• Price to Earnings (P/E): 14.7
• Beta (1Y): 1.07
• Revenue Growth: -3.82%
• EPS Growth: -50.36%
• Country: CA
• Employees: 82
• Sector: Healthcare
• Sector Strength: 48
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.04
• Shares Outstanding: 32,258,354
• 10 Day Avg. Volume: 27,590
• 30 Day Avg. Volume: 46,907
• PEG Ratio: 0.19
• Price to Book (P/B): 1.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 2.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$8.00
• Price Target Upside: 193.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Medexus Pharmaceuticals demonstrates solid financial recovery and strategic growth potential, particularly with new product launches like GRAFAPEX. While technical indicators suggest caution, the company's strategic initiatives and recent achievements, including FDA approvals and reimbursement agreements, provide a strong foundation for future performance. High leverage and competitive pressures remain as potential risks.

Positive Factors

Financial Performance

Medexus's FQ3 results were ahead of initial estimates, showing strong performance.

Regulatory Approval

U.S. FDA approves Treosulfan, marking a significant benefit to patients.

Negative Factors

Generic Risk

There is generic risk in the base business with Rupall losing exclusivity.

Pricing Assumptions

Initial pricing assumptions for GRAFAPEX appear optimistic.

Regulatory Setback

Medexus faces a negative Health Canada setback for Terbinafine.

Medexus Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Medexus Pharmaceuticals Inc. (MDP) is a specialty pharmaceutical company operating primarily in North America. The company focuses on the acquisition, licensing, and distribution of innovative and high-value medications across various therapeutic areas including autoimmune diseases, hematology, and allergies. Medexus aims to address unmet medical needs by delivering products that improve patient outcomes and quality of life.

How the Company Makes Money

Medexus Pharmaceuticals Inc. generates revenue through the sale of its pharmaceutical products to healthcare providers, hospitals, and pharmacies. The company's revenue model is based on distributing licensed and proprietary medications in key therapeutic areas. Medexus also engages in strategic partnerships and licensing agreements to expand its product portfolio and market reach. These partnerships enable Medexus to access new markets and increase its revenue potential by leveraging the established networks and expertise of its partners. Additionally, Medexus may earn milestone and royalty payments from licensing agreements, contributing to its overall earnings.

Medexus Pharmaceuticals Inc Financial Statement Overview

Summary

Medexus Pharmaceuticals Inc exhibits a strong recovery trajectory with improvements in profit margins and cash flows. While leverage remains a concern, the company shows promising revenue growth and better cash management, positioning it well in the pharmaceuticals sector.

Income Statement

The company shows strong revenue growth, particularly in the last two years, with a notable improvement in EBIT and EBITDA margins. Gross profit margins remain healthy, despite past challenges in net income. The recent TTM data highlights a positive trajectory, though historical volatility in net profit margin indicates potential risks.

Balance Sheet

The debt-to-equity ratio has improved, reflecting better leverage management, though it remains relatively high. The equity ratio is stable, and the recent return to positive net income is encouraging. However, historical high leverage and fluctuating equity levels pose potential risks.

Cash Flow

Operating and free cash flows have shown robust growth, significantly enhancing cash flow stability. Free cash flow to net income ratio is strong, indicating efficient cash generation relative to profit. Past volatility is overshadowed by recent positive trends.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
109.54M	113.05M	108.10M	76.70M	79.66M	52.43M
	Gross Profit
57.46M	59.51M	60.04M	37.93M	42.01M	29.44M
	EBIT
10.22M	10.79M	7.61M	-15.00M	-1.38M	―
	EBITDA
18.48M	19.28M	14.65M	15.16M	-23.61M	7.04M
	Net Income Common Stockholders
3.56M	-214.00K	1.22M	-2.88M	-28.26M	―
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
576.32K	5.25M	13.07M	10.02M	18.70M	5.23M
	Total Assets
592.16K	155.73M	161.33M	139.22M	148.51M	122.81M
	Total Debt
0.00	49.90M	70.08M	54.86M	44.87M	38.81M
	Net Debt
-576.32K	44.64M	57.01M	44.84M	26.17M	33.58M
	Total Liabilities
15.84K	125.41M	138.88M	121.43M	130.50M	98.53M
	Stockholders Equity
576.32K	30.32M	22.45M	17.79M	18.02M	24.28M
Cash Flow		Free Cash Flow
20.47M	18.45M	-1.81M	-8.89M	-5.72M	―
	Operating Cash Flow
23.36M	18.71M	-1.44M	-1.18M	5.04M	―
	Investing Cash Flow
-4.48M	-3.48M	-1.72M	-8.20M	-11.70M	―
	Financing Cash Flow
-18.33M	-23.05M	6.41M	663.00K	18.68M	14.60M

Medexus Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.73
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDP, the sentiment is Neutral. The current price of 2.73 is above the 20-day moving average (MA) of 2.65, above the 50-day MA of 2.54, and below the 200-day MA of 2.77, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 53.58 is Neutral, neither overbought nor oversold. The STOCH value of 63.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MDP.

Medexus Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDP	71 Outperform	C$94.19M	14.66	11.27%	―	-3.82%	-50.36%
GUD	64 Neutral	$582.77M	52.84	1.41%	―	12.21%	―
HLS	60 Neutral	C$143.07M	―	-23.05%	―	-3.73%	32.70%
TH	54 Neutral	$165.99M	―		―	16.23%	85.76%
Sector *	52 Neutral	$5.21B	3.49	-43.30%	2.83%	14.70%	-0.24%
PHA	50 Neutral	C$4.16M	―	-160.58%	―	44.96%	-827.30%

Medexus Pharmaceuticals Inc Corporate Events

Medexus Secures Public Reimbursement for Trecondyv® in Quebec

Medexus Pharmaceuticals Inc. has successfully secured a public reimbursement agreement for Trecondyv® (treosulfan for injection) with Quebec’s provincial government, marking a significant milestone as it now has public reimbursement in Canada’s three most populous provinces. This achievement underscores Medexus’s commitment to expanding access to Trecondyv® across Canada, enhancing its market position and potentially benefiting stakeholders by increasing the availability of this treatment for patients with acute myeloid leukemia and myelodysplastic syndromes.

Spark’s Take on TSE:MDP Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDP is a Outperform.

Medexus Pharmaceuticals Inc. demonstrates strong financial recovery with significant growth potential from new product launches like GRAFAPEX. Despite technical indicators pointing to a bearish trend, the company’s strategic positioning and recent achievements, such as FDA approvals and successful equity offerings, support a solid foundation for future performance. Valuation metrics suggest potential undervaluation, although challenges such as high leverage and competitive pressures remain.

To see Spark’s full report on TSE:MDP stock, click here.

Medexus Reports Strong Initial Uptake of GRAFAPEX™ in U.S. Market

Medexus Pharmaceuticals has reported a positive initial market response to the commercial launch of GRAFAPEX™ (treosulfan) for Injection in the United States. The product has been included in several formularies, and its uptake aligns with company expectations, suggesting strong commercial potential. The company anticipates that GRAFAPEX™ will significantly contribute to its financial performance, expecting it to be accretive to quarterly operating cash flows by fiscal Q4 2026. Additionally, the medical community’s engagement, as evidenced by numerous presentations at a recent congress, supports the company’s confidence in GRAFAPEX™’s impact on the alloHSCT market in the U.S.

Spark’s Take on TSE:MDP Stock

According to Spark, TipRanks’ AI Analyst, (TSE:MDP) is a Neutral.

Medexus Pharmaceuticals is showing promising financial recovery and strategic positioning with the launch of GRAFAPEX. While technical indicators are mixed, and leverage remains a concern, the company’s growth potential and recent achievements provide a solid foundation for future performance.

To see Spark’s full report on (TSE:MDP) stock, click here.

Medexus Returns Gleolan U.S. Rights to NX Development Corp.

Medexus Pharmaceuticals has finalized an agreement with NX Development Corp. to return the U.S. commercialization rights for Gleolan, a move that will see NXDC assume responsibility for the product by March 31, 2025. This strategic decision allows Medexus to receive a per-unit payment on Gleolan sales through June 2025, aligning with the company’s interests and ensuring continued availability of the product for patients, while potentially reducing royalty obligations.

Medexus Launches GRAFAPEX in US, Eyes $100M Revenue

Medexus Pharmaceuticals Inc has announced the commercial availability of GRAFAPEX (treosulfan) for Injection in the United States, marking a significant milestone for the company. This product, used as a preparative regimen for allogeneic hematopoietic stem cell transplantation, is expected to greatly enhance Medexus’s market position in the hemato-oncology space. The company anticipates that the annual revenue from GRAFAPEX in the U.S. could exceed $100 million within five years, reinforcing its strategic importance. This development comes shortly after receiving FDA approval and has already generated positive feedback from key institutions, indicating a strong potential impact on Medexus’s operations and revenue growth.

Medexus Pharmaceuticals Reports Strong Q3 2025 Results Amidst Strategic Growth

Medexus Pharmaceuticals reported strong fiscal Q3 2025 results with a revenue of $30.0 million, a net income of $0.7 million, and an operating income of $3.8 million. The company attributed the revenue growth to increased sales of Rupall and favorable customer buying patterns for IXINITY, while also noting reduced sales of Rasuvo and Metoject. The company’s financial discipline and strategic investments in personnel and infrastructure for GRAFAPEX™ have contributed to these results, positioning Medexus well for the upcoming U.S. launch of GRAFAPEX.